Diabetes and mortality following acute coronary syndromes.

By S. M. Donahoe, G. Stewart, C. Mccabe, Satishkumar Mohanavelu, S. Murphy, C. Cannon, E. Antman. Journal of the American Medical Association (JAMA), 2007

721 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/8c01bf494a151b0ad7acc40a84087c68c256b555

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Rhian M. Touyz
2. Marja-Riitta Taskinen
3. I. Graham
4. Gerhard Hindricks
5. Stephan Windecker

In Endocrinology, Diabetes and Metabolism

1. Marja-Riitta Taskinen
2. I. Graham
3. Alberico L. Catapano
4. Rhian M. Touyz

Citations in the corpus

• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “408 Importantly, DM confers excess mortality risk following ACS despite modern therapies, highlighting the poor prognosis of coronary patients with T2DM and the need for intensive therapy.(409) How to capture the extra risk beyond the traditional risk factors in clinical practice is a debated issue.”
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, background): “Importantly, diabetes confers excess mortality risk following ACS despite modern therapies, highlighting the poor prognosis of coronary patients with T2DM and the need for intensive therapy.(345)”
• Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association (2016, background): “For both men and women with DM, mortality after STEMI or UA/NSTEMI is significantly increased compared with their nondiabetic counterparts at 30 days and 1 year.(174) by gest on M arch (1)0, 2018 http://ciajournals.”